Cannassure Therapeutics (Israel) Performance
| CSURE Stock | 950.00 118.00 11.05% |
The firm shows a Beta (market volatility) of 0.74, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Cannassure Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cannassure Therapeutics is expected to be smaller as well. At this point, Cannassure Therapeutics has a negative expected return of -0.5%. Please make sure to confirm Cannassure Therapeutics' potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Cannassure Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Cannassure Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Other Cashflows From Financing Activities | 134 K | |
| Total Cashflows From Investing Activities | -4.2 M |
Cannassure |
Cannassure Therapeutics Relative Risk vs. Return Landscape
If you would invest 163,900 in Cannassure Therapeutics on September 12, 2024 and sell it today you would lose (57,100) from holding Cannassure Therapeutics or give up 34.84% of portfolio value over 90 days. Cannassure Therapeutics is generating negative expected returns and assumes 8.9886% volatility on return distribution over the 90 days horizon. Simply put, 80% of stocks are less volatile than Cannassure, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Cannassure Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cannassure Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cannassure Therapeutics, and traders can use it to determine the average amount a Cannassure Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0558
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CSURE |
Estimated Market Risk
| 8.99 actual daily | 80 80% of assets are less volatile |
Expected Return
| -0.5 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cannassure Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cannassure Therapeutics by adding Cannassure Therapeutics to a well-diversified portfolio.
Cannassure Therapeutics Fundamentals Growth
Cannassure Stock prices reflect investors' perceptions of the future prospects and financial health of Cannassure Therapeutics, and Cannassure Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cannassure Stock performance.
| Return On Equity | -2.11 | |||
| Return On Asset | -0.52 | |||
| Profit Margin | (1.53) % | |||
| Operating Margin | (1.52) % | |||
| Current Valuation | 56.54 M | |||
| Shares Outstanding | 51.17 M | |||
| Price To Sales | 0.05 X | |||
| Revenue | 16.32 M | |||
| EBITDA | (20.64 M) | |||
| Book Value Per Share | 0.14 X | |||
| Cash Flow From Operations | (20.82 M) | |||
| Earnings Per Share | (0.31) X | |||
About Cannassure Therapeutics Performance
Assessing Cannassure Therapeutics' fundamental ratios provides investors with valuable insights into Cannassure Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Cannassure Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about Cannassure Therapeutics performance evaluation
Checking the ongoing alerts about Cannassure Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cannassure Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cannassure Therapeutics generated a negative expected return over the last 90 days | |
| Cannassure Therapeutics has high historical volatility and very poor performance | |
| The company reported the revenue of 16.32 M. Net Loss for the year was (28.54 M) with loss before overhead, payroll, taxes, and interest of (14.17 M). | |
| Cannassure Therapeutics generates negative cash flow from operations | |
| About 51.0% of the company shares are held by company insiders |
- Analyzing Cannassure Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cannassure Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Cannassure Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cannassure Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cannassure Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cannassure Therapeutics' stock. These opinions can provide insight into Cannassure Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Cannassure Stock Analysis
When running Cannassure Therapeutics' price analysis, check to measure Cannassure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannassure Therapeutics is operating at the current time. Most of Cannassure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cannassure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannassure Therapeutics' price. Additionally, you may evaluate how the addition of Cannassure Therapeutics to your portfolios can decrease your overall portfolio volatility.